MyPeBS en questions


MyPeBS (My Personal Breast Screening) is a clinical trial that is currently in progress.
This European trial, which is expected to last 6 years and enroll 80,000 women, is designed to assess the interest of individualized screening based on personal risk of developing breast cancer.

At first glance, this clinical trial appears to be of interest. Unfortunately, when we examine the protocol, we quickly notice that the trial's promoters have a clear pro-screening bias. And because of this bias, they made questionable decisions, resulting in serious flaws in MyPeBS.

Of course, these flaws are not mentioned on the official MyPeBS website. Nonetheless, it appears to me that both the doctors who are asked to be investigators and the women who are offered to participate in the trial have a right to complete information on MyPeBS's strengths and weaknesses.
We can rely on the MyPeBS official website for the strengths. This website's vocation is to address the flaws.

Furthermore, it is difficult to make an informed decision about MyPeBS without first understanding the current uncertainties surrounding the benefit/risk ratio of breast cancer screening as it is currently practiced. For this reason, a section of the site is dedicated to an overview of breast cancer screening.

This website is divided into three sections :

- a critical analysis of MyPeBS

- a critical analysis of current breast cancer screening methods

updates on MyPeBS and breast cancer screening

Last news

01/11/2021 - Early clinical diagnosis as effective as screening.
The Lancet Oncology has published a study suggesting that early clinical diagnosis may be as effective as screening in avoiding advanced cancers and reducing breast cancer mortality.     Read more

19/10/2021 - The new INCa leaflet: again soliciting rather than informing.
Since June 2021, the INCa (National Cancer Institute) has published a new leaflet promoting screening. In this new leaflet, INCa clearly continues to conflate solicitation and information.     Read more

16/08/2021 - A new example of semantic shift: from non-inferior to more beneficial.
The MGEN mutual insurance company invites its members to take part in MyPeBS through its website. Once again (see news of 19/07/21) MyPeBS is presented as a study aimed at demonstrating the superiority of an individualized screening over the current screening.     Read more

19/07/2021 - Semantic shift from non-inferior to possibly superior. A good example!
The insurance and pension fund (CPR SNCF) of the French National Railways (SNCF) sends an email to women insured inviting them to participate in the MyPeBS study. Although MyPeBS is a non-inferiority study, the letter states that « researchers will assess whether personalized screening would be more effective than the one currently organized. »    Read more

28/06/2021 - To inform or to promote, one has to choose. The INCa's conflict of interest.
The INCa openly expresses its determination to promote breast cancer screening at all costs, even if it means deliberately withholding information from women and censoring the media if they want to report on it.     Read more

Dernière mise à jour le 05/11/2021